AbbVie’s disappointing schizophrenia drug trial bodes well for
The outcome of AbbVie’s emraclidine trial could also bode well Neurocrine Biosciences Inc. in its efforts to develop a schizophrenia drug, according to Evercore ISI. “This news may also prove ...
AbbVie's disappointing schizophrenia drug trial bodes well for …
2 days ago · AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie (ABBV) said that its Phase 2 trial ...
AbbVie Tumbles After New Schizophrenia Drug Fails in Two Trials
3 days ago · AbbVie Inc. shares sank in early trading after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion acquisition of ...
AbbVie Drug Expected to Rival Bristol Myers’s New Schizophrenia …
4 days ago · AbbVie schizophrenia drug candidate emraclidine failed to beat a placebo in two Phase 2 clinical trials. The drug, once projected to compete with Bristol Myers Squibb’s Cobenfy, is from AbbVie ...
AbbVie's closely watched schizophrenia drug fails two studies, …
3 days ago · AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, widening rival Bristol Myers Squibb's lead in the market ...
Schizophrenia drug AbbVie picked up in $9 billion acquisition
3 days ago · Nov. 11, 2024. National Biotech Reporter. AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got ...
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints ...
3 days ago · The disappointing AbbVie’s trial results is a benefit for Bristol Myers Squibb & Co’s (NYSE:BMY) approved schizophrenia drug, Cobenfy, but they raise questions about using selective muscarinic ...
AbbVie Shares Fall Premarket After Schizophrenia Drug Study …
3 days ago · By Colin Kellaher. AbbVie said its recently acquired emraclidine drug candidate for schizophrenia missed the key goal in a pair of mid-stage studies, sending the biopharmaceutical company's shares ...
AbbVie Shares Slide, Bristol Myers Shares Rise After Schizophrenia ...
3 days ago · By Colin Kellaher. AbbVie said the schizophrenia drug candidate at the center of its recent $8.7 billion acquisition of Cerevel failed in a pair of mid-stage studies, sending the biopharmaceutical ...
AbbVie shares tumble after schizophrenia drug disappoints
3 days ago · Shares in AbbVie tumbled after the drugmaker revealed that an experimental treatment for schizophrenia, the main drug purchased as part of an $8.7bn acquisition last year, failed to meet its goals ...
- Some results have been removed